Skip to content

A clinical trial to study effect of topical application of Argyreia Speciosa gel as an adjunct to scaling in tobacco users having gingivitis patients

Comparative evaluation of anti-plaque and anti-inflammatory effect of topical application of Argyreia Speciosa gel as an adjunct to scaling in Tobacco users: A clinical study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/08/073113
Enrollment
60
Registered
2024-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K051- Chronic gingivitis

Interventions

Intervention1: Topical Application of Argyreia Speciosa Gel as an adjunct to scaling: After scaling patients will be asked to apply topical application of Argyreia Speciosa Gel 3 times a day for 15

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Chronic gingivitis patients with a minimum of 16 gradable teeth. 2) Patients with history of deleterious habits (i.e., use of tobacco consumption etc.) 3) Systemically healthy patients. 4) Patients requiring scaling. 5) Both males and females between the age group of 20-60 year with = 3 mm of probing depth (PD). 6) Patient not on systemic antibiotics for the past 3 months. 7) No use of anti-inflammatory drugs within the past 3 months 8) Availability of the patient for the entire duration of the study. 9) Not receiving periodontal treatment within last 6 months. 10) Patient should be able to understand and give a written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with systemic diseases (i.e., diabetes mellitus, cancer, HIV, bone metabolic diseases). 2) Patients on systemic corticosteroids, immunosuppressive agents, radiation therapy, and/or chemotherapy prescribed or received within 2 months prior to study entry. 3) Pregnant and/or lactating females. 4) Patients contraindicated for scaling.

Design outcomes

Primary

MeasureTime frame
Reduction in gingival inflammation and plaque formationTimepoint: Baseline to 15 days.

Secondary

MeasureTime frame
-Timepoint: -

Countries

India

Contacts

Public ContactDr Kedar Kulkarni

SMBT Dental College and Hospital

dr.saurabh.subhash.patil@gmail.com9325596570

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026